Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 75 years of age~* Diagnosis of heterozygous familial hypercholesterolemia by having met the diagnostic criteria outlined by the Simon Broome Register Group (Scientific Steering Committee 1991)~* On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks~* Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* Homozygous familial hypercholesterolemia~* Low-Density Lipoprotein (LDL) or plasma apheresis within 12 months prior to randomization~* New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization~* Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (HbA1c \> 8.5%)~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).